ArticleBrazilian journal of otorhinolaryngology
The effectiveness of propranolol, flunarizine, amitriptyline and botulinum toxin in vestibular migraine complaints and prophylaxis: a non-randomized controlled study.
Article in Brazilian journal of otorhinolaryngology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06162819 (Efficacy of Flunarizine Vs Amitriptyline in Prophylaxis of Migraine Prophylaxis), which is not on this map. Cited by 13 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Flunarizine Vs Amitriptyline in Prophylaxis of Migraine Prophylaxis
Who cites it
13 citing papers in PubMed, 4 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Comparative effectiveness and safety of preventive treatments for vestibular migraine: a systematic review and network meta-analysis.BMC neurology · 2025Pooled it
- Pooled it
- Vestibular migraine treatment: a comprehensive practical review.Brain : a journal of neurology · 2022Pooled it
- Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review.Pain research & management · 2022Pooled it
- Flunarizine and cinnarizine in the prophylaxis of vestibular migraine and migraine-associated menière's disease: An 8-month retrospective study.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Persistent postural-perceptual dizziness versus vestibular migraine: A narrative review.Headache · 2026Review
- Therapeutic Management of Vestibular Disorders During Pregnancy: A Narrative and Evidence-Based Review.Cureus · 2025Review
- Efficacy of Low-Dose BoNT-A Acupoint Injections in Managing Headache, Vertigo, and Allodynia in Vestibular Migraine.The journal of international advanced otology · 2025Article
- Insights into Vestibular Migraine: Diagnostic Challenges, Differential Spectrum and Therapeutic Horizons.Journal of clinical medicine · 2025Review
- Vestibular Migraine Pathophysiology and Treatment: a Narrative Review.Current pain and headache reports · 2024Review
- Migraine management for the otolaryngologist.Laryngoscope investigative otolaryngology · 2023Review
- Management of Migraine-Associated Vestibulocochlear Disorders.Audiology research · 2023Review
- Effects of flunarizine combined with ginkgo leaf extract and dipyridamole injection on hemorheology in elderly patients with vertigo.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVestibular migraine is the most common cause of spontaneous episodic vertigo in adult patients and the second most common cause of vertigo in patients of all ages.
objectiveTo assess the effectiveness of oral medication type (propranolol, flunarizine, and amitriptyline) and botulinum toxin A application on vestibular symptoms, headache severity and attack frequency for vestibular migraine patients.
methodsSixty patients with vestibular migraine were enrolled. Thirty patients received botulinum toxin A treatment (B+ group) in addition to the oral medication, whereas 30 patients received only oral medication (B- group). Headache severity was evaluated with Migraine Disability Assessment Scale and vertigo severity was evaluated with Dizziness Handicap Inventory scale. Vestibular migraine attack frequencies in the last three months were also evaluated.
resultsThere was a statistically significant decrement in mean Dizziness Handicap Inventory scores, Migraine Disability Assessment Scale scores and vertigo attack frequencies after treatment for all patients, B+ and B- group patients (p<0.001 for all). The mean Migraine Disability Assessment Scale score gains (p<0.001) and vertigo attack frequency gains (p= 0.003) were significantly higher in the B+ patients than B- patients.
conclusionsBoth B+ and B- group patients exhibited significant improvement in vestibular migraine attack frequencies, Dizziness Handicap Inventory score and Migraine Disability Assessment Scale score values. However, botulinum toxin A application had a more pronounced effect for Migraine Disability Assessment Scale score gain and vestibular migraine attack frequency values, but not for Dizziness Handicap Inventory score gain values. Thus, botulinum toxin A application should be considered for vestibular migraine patients whose headache severity degrees are more profound. The oral medication type (propranolol, flunarizine or amitriptyline) did not differ in influencing the vestibular migraine attack frequency, Dizziness Handicap Inventory score gain and Migraine Disability Assessment Scale score gain values.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.